A novel antibody based therapy for allergy

• Research unit: INNOSUISSE
• Project number: 13385.1;4 PFFLR-LS

Short description (German)

A novel antibody based therapy for allergy

Short description (English)

A novel antibody based therapy for allergy

Abstract (German)

We intend to develop bispecific antibodies that target specifically IgE bearing B cells. Such bispecific antibodies will be evaluated for their capacity to inhibit IgE synthesis as well as to knock out IgE bearing B cells. The development of such antibodies represent an innovative approach as current therapeutic IgE-specific antibodies do not affect IgE production and therefore must be given frequently to maintain sufficient suppression of serum IgE. Glenmark has developed the necessary expression systems for bispecific antibodies and has all license agreement to market such antibodies. The academic partner has the individual anti-IgE antibodies that will be used for the construction of bispecific antibodies and will perform the preclinical testing in order to decide which construct will be taken up in the production pipeline.

Abstract (English)

We intend to develop bispecific antibodies that target specifically IgE bearing B cells. Such bispecific antibodies will be evaluated for their capacity to inhibit IgE synthesis as well as to knock out IgE bearing B cells. The development of such antibodies represent an innovative approach as current therapeutic IgE-specific antibodies do not affect IgE production and therefore must be given frequently to maintain sufficient suppression of serum IgE. Glenmark has developed the necessary expression systems for bispecific antibodies and has all license agreement to market such antibodies. The academic partner has the individual anti-IgE antibodies that will be used for the construction of bispecific antibodies and will perform the preclinical testing in order to decide which construct will be taken up in the production pipeline.